A new synthetic toll-like receptor 1/2 ligand is an efficient adjuvant for peptide vaccination in a human volunteer.
Hans-Georg RammenseeKarl-Heinz WiesmüllerP Anoop ChandranHenning ZelbaElisa RuschCécile GouttefangeasDaniel J KowalewskiMoreno Di MarcoSebastian P HaenJuliane S WalzYamel Cardona GloriaJohanna BödderJill-Marie SchertelAntje TungerLuise MüllerMaximilian KießlerRebekka WehnerMarc SchmitzMeike JakobiNicole Schneiderhan-MarraReinhild KleinKaroline LaskeKerstin ArtznerLinus BackertHeiko SchusterJohannes SchwenckAlexander N R WeberBernd J PichlerManfred KneillingChristian la FougèreStephan ForchhammerGisela MetzlerJürgen BauerBenjamin WeideWilfried SchippertStefan StevanovićMarkus W LöfflerPublished in: Journal for immunotherapy of cancer (2019)
Thus, in one volunteer we show a granuloma forming by peptides combined with an efficient adjuvant in a water-in-oil-emulsion, inducing antigen specific T cells detectable in circulation and at the vaccination site, after one single vaccination only. The ex vivo T cell responses in peripheral blood were detectable for more than one year and could be strongly boosted by a second vaccination. Hence, XS15 is a promising adjuvant candidate for peptide vaccination, in particular for tumor peptide vaccines in a personalized setting.